Requires a weekly update of the department of health's prescription drug retail price list.
Summary
Bill S00437 aims to amend the public health law in New York by requiring the Department of Health to maintain and update a prescription drug retail price list on a weekly basis. This list will include the actual prices that retail purchasers pay for commonly prescribed drugs, specifically the one hundred fifty most frequently prescribed drugs, as reported by pharmacies participating in the medical assistance program. The bill mandates that pharmacies provide their usual and customary price data to the Department of Health, ensuring that the price list reflects current market conditions and is accessible to the public.
Impact
The implementation of this bill will enhance transparency in prescription drug pricing by providing consumers with up-to-date information on retail prices. It will require pharmacies to regularly report pricing data, which could lead to increased competition among pharmacies and potentially lower drug prices for consumers. Additionally, the bill aligns with state and federal privacy and confidentiality requirements, ensuring that consumer information is protected while making pricing data available.
Sentiment
The general sentiment surrounding Bill S00437 appears to be supportive, as it addresses the critical issue of prescription drug pricing transparency. However, there may be concerns regarding the administrative burden placed on pharmacies to report pricing data weekly and the potential implications for smaller pharmacies that may struggle to comply with the new requirements.
Contention
Notable points of contention include the potential administrative challenges for pharmacies, particularly smaller establishments, in providing the required data on a weekly basis. Some stakeholders may argue that the bill could disproportionately affect these smaller pharmacies, while others advocate for the increased transparency and consumer access to pricing information. There may also be discussions regarding the adequacy of the proposed penalties for non-compliance with the reporting requirements.
Requires prescription drug manufacturers to file a detailed, updated list of each pharmaceutical sales representative engaged by the manufacturer and to pay an annual fee for each name listed with the department of business regulation.
Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.